Working… Menu

Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00746590
Recruitment Status : Terminated (Study terminated prematurely by sponsor for business reason. One patient was enrolled.)
First Posted : September 4, 2008
Results First Posted : June 9, 2016
Last Update Posted : June 9, 2016
Information provided by (Responsible Party):
BTG International Inc.

Brief Summary:

This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix in subjects with advanced hepatocellular carcinoma.

Prolarix is a chemotherapy comprised of tretazicar as prodrug and caricotamide as co-substrate for the endogenous enzyme, NQO2.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: Prolarix (tretazicar co-administered with caricotamide) Phase 2

Detailed Description:

The primary objective of this study is to evaluate the anti-tumour effects of treatment with Prolarix in subjects with advanced HCC (Child-Pugh A and B only).

All subjects will receive an IV infusion of Prolarix once every 21 days until disease progression is observed.

Subjects will have CT scans for tumour measurements before starting treatment with Prolarix and every 6 weeks until disease progression.

Subjects will undergo evaluation for safety (adverse events, vital signs, clinical laboratory measurements, weight, ECG) every 21 days until disease progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of the Anti-tumour Activity and Safety of Prolarix™ in Hepatocellular Carcinoma (HCC)
Study Start Date : September 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : August 2009

Arm Intervention/treatment
Experimental: 1 Drug: Prolarix (tretazicar co-administered with caricotamide)
Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
Other Name: Prolarix

Primary Outcome Measures :
  1. Overall Best Tumor Response Rate (Proportion of Subjects With Complete or Partial Response) as Defined by Modified RECIST [ Time Frame: every 6 weeks until progression ]

Secondary Outcome Measures :
  1. Disease Control Rate Defined as the Proportion of Subjects With Either Complete or Partial Response or Stable Disease [ Time Frame: Approximately 12 weeks or more after first treatment with Prolarix ]
  2. Time to Tumour Progression [ Time Frame: Every 3 weeks until progression ]
  3. Post-treatment Changes in the Amount of Contrast-enhancing and Non-contrast-enhancing Tumour [ Time Frame: Every 6 weeks until progression ]
  4. Changes in Alpha Fetoprotein [ Time Frame: Baseline, every 3 weeks until progression ]
  5. Adverse Events [ Time Frame: Until progression ]
  6. Changes in Laboratory Measurements [ Time Frame: Baseline and every 3 weeks until progression ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must be at least 18 years of age.
  • Subject must have a histologic or cytologic diagnosis of HCC and be considered unsuitable for resection or other potentially curative options (eg, liver transplant, curative radiofrequency ablation).
  • Subject must have a measurable lesion by RECIST on CT scan in at least one site which has not received radiation or any other local therapy [eg, transcatheter arterial chemoembolisation (TACE), radiofrequency ablation, local injection]. (Note: Subjects who have received local therapies will be allowed to participate, provided that they have a target lesion which has not been subjected to local therapy. Subjects who have received TACE must have a target lesion outside of the vascular territory subjected to chemoembolisation.)
  • Subject has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
  • Subject has had no other active malignancy within the past three years [other than non melanomatous skin cancer or carcinoma in situ (CIS) of the breast, bladder, or uterine cervix. Subjects with Ta (non-invasive papillary carcinoma) or Tis (sessile carcinoma in situ) bladder cancer are allowed].
  • Subject has a minimum life expectancy of at least three months as determined by the investigator.
  • Subject has adequate bone marrow function (ie, haemoglobin ≥9 g/dL, granulocytes ≥1500/mm3, platelets ≥75,000/mm3).
  • Prothrombin time (PT)-international normalised ratio (INR) ≤2.3 or PT ≤6 seconds above control. (Note: Subjects who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that their INR is between 2.0 and 3.0.
  • Subject has adequate renal function (ie, serum creatinine is normal or calculated creatinine clearance is ≥60 mL/min).
  • Subject has adequate hepatic function (ie, bilirubin ≤2x upper limit of normal (ULN); AST ALT, and alkaline phosphatase ≤5xULN). (Also see exclusion for Child-Pugh class C below).
  • Male subjects and females of childbearing potential must agree to use an adequate method of contraception from the time of initiation of treatment through study participation and for 3 months after release from the study.
  • Subject is able to give informed consent.

Exclusion Criteria:

  • Any prior or current systemic pharmacotherapy for HCC (cytotoxic, targeted or biologic). (Note: TACE is not considered to be systemic pharmacotherapy for the purpose of this study).
  • Subject has an absolute contraindication to receiving CT contrast media. (Note: Subjects with a history of minor contrast reactions may be pre-medicated prior to contrast administration in accordance with local or institutional practice).
  • Subject has Child-Pugh Class C hepatic impairment.
  • Subject has received an investigational drug within 30 days of enrolment in the study.
  • Females of childbearing potential unless using adequate contraception.
  • Pregnant or lactating females.
  • Major variceal bleeding in the last 30 days.
  • Subjects with a known history of human immunodeficiency virus (HIV) infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00746590

Layout table for location information
Cliniques Universitaires Saint-Luc
Brussels, Belgium, 1200
Sponsors and Collaborators
BTG International Inc.
Layout table for investigator information
Study Director: Claire Daugherty, MS BTG International Inc.
Layout table for additonal information
Responsible Party: BTG International Inc. Identifier: NCT00746590    
Other Study ID Numbers: PR003-CLN-pro001
First Posted: September 4, 2008    Key Record Dates
Results First Posted: June 9, 2016
Last Update Posted: June 9, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by BTG International Inc.:
hepatocellular carcinoma
liver cancer
Phase 2
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents